Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$275.39
$242.67
$188.08
▼
$282.15
$17.18B0.4701,749 shs826,059 shs
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
$57.23
$58.86
$49.26
▼
$70.98
$11.09B0.212.47 million shs1.47 million shs
7 Best Space Stocks to Own in 2026 Cover

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
0.00%+7.23%+22.26%+11.31%+34.73%
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
0.00%+2.14%+4.66%-14.12%+4.57%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$275.39
$242.67
$188.08
▼
$282.15
$17.18B0.4701,749 shs826,059 shs
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
$57.23
$58.86
$49.26
▼
$70.98
$11.09B0.212.47 million shs1.47 million shs
7 Best Space Stocks to Own in 2026 Cover

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
0.00%+7.23%+22.26%+11.31%+34.73%
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
0.00%+2.14%+4.66%-14.12%+4.57%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
2.90
Moderate Buy$313.5213.85% Upside
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
2.80
Moderate Buy$87.2252.40% Upside

Current Analyst Ratings Breakdown

Latest ASND and BMRN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/13/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
UpgradeHold (C) ➝ Hold (C+)
11/13/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Set Price Target$352.00
11/13/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Reiterated RatingOutperform
11/13/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Boost Price TargetOverweight$326.00 ➝ $330.00
11/13/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Set Price Target$330.00
11/13/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Boost Price TargetBuy$269.00 ➝ $315.00
11/13/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Reiterated RatingOutperform$290.00
11/13/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Boost Price TargetBuy$341.00 ➝ $352.00
11/13/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Boost Price TargetHold$268.00 ➝ $274.00
11/13/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Boost Price TargetOverweight$300.00 ➝ $315.00
11/13/2026
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
Lower Price TargetOverweight$119.00 ➝ $103.00
(Data available from 11/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$814.57M21.09N/AN/A($2.97) per share-92.72
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
$3.22B3.44$2.85 per share20.06$31.68 per share1.81
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
-$258M$15.3018.0030.63N/A73.26%32.47%13.26%N/A
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
$348.90M-$0.1032.1511.130.77-0.52%5.58%3.51%N/A

Latest ASND and BMRN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/2/2026Q3 2026
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
-$0.0493$0.23+$0.2793-$0.63$1.02 billion$1.02 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
N/AN/AN/AN/AN/A
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
0.25
2.89
2.29
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
0.56
2.44
1.32

Institutional Ownership

CompanyInstitutional Ownership
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
N/A
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
98.71%

Insider Ownership

CompanyInsider Ownership
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
40.00%
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
0.68%
CompanyEmployeesShares OutstandingFree FloatOptionable
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
1,18962.38 million37.43 millionOptionable
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
3,221193.70 million192.38 millionOptionable

Recent News About These Companies

BioMarin Pharmaceutical (BMRN) Receives a Buy from Evercore ISI
BioMarin: Better Risk-Reward Ahead Of Three FDA Decisions

New MarketBeat Followers Over Time

Media Sentiment Over Time

Ascendis Pharma A/S stock logo

Ascendis Pharma A/S NASDAQ:ASND

$275.39 0.00 (0.00%)
Closing price 11/13/2026 04:00 PM Eastern
Extended Trading
$275.74 +0.36 (+0.13%)
As of 04:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

BioMarin Pharmaceutical stock logo

BioMarin Pharmaceutical NASDAQ:BMRN

$57.23 0.00 (0.00%)
Closing price 11/13/2026 04:00 PM Eastern
Extended Trading
$56.95 -0.28 (-0.49%)
As of 04:13 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc. The company was incorporated in 1996 and is headquartered in San Rafael, California.